Trial Profile
A Multi-Center, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Osilodrostat (Primary) ; Eplerenone
- Indications Essential hypertension
- Focus Therapeutic Use
- 11 Jun 2021 Number of treatment arms have been increased from 6 to 17, by the addition of 11 new arms as "withdrawal period" and re-labeling the remaining arms as "core-period".
- 10 Oct 2011 Results published in the Circulation.
- 16 Mar 2010 Results were presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC-2010).